Results from Solitaire with the Intention for Thrombectomy (SWIFT) Study Announced at the International Stroke Conference on February 3

- Thursday, February 2nd 2012 [ME NewsWire]

(BUSINESS WIRE)-- Covidien:
                                   

WHO:
                                 

Jeffrey Saver, MD
                                   

SWIFT, Lead Author
                                   

Professor of Neurology and Director
                                   

UCLA Stroke Center, David Geffen School of Medicine
                                   

University of California, Los Angeles
                                   

WHAT:
                                 

Results from the Solitaire with the Intention for Thrombectomy (SWIFT) Study will be announced at a press conference at 8AM CT – followed by a late breaking trial presentation at 12 PM CT. The Solitaire™ FR Revascularization Device is a stent-based mechanical thrombectomy system from Covidien. It combines the ability to revascularize and retrieve the clot in a single device. The device is designed to be passed through the obstruction and deployed, thereby offering the potential for flow restoration and the ability to retrieve clots in patients experiencing acute ischemic stroke. The objective of the SWIFT study is to demonstrate substantial equivalence in the safety and effectiveness of the Solitaire™ FR Revascularization Device when compared to the MERCI® Retrieval.
                                   

WHERE:
                                 

International Stroke Conference
                                   

Ernest N. Morial Convention Center
                                   

- Press Conference: News Media Center Room 211
                                   

- SWIFT Presentation Dr Saver: Hall D
                                   

900 Convention Center Blvd.
                                   

New Orleans
                                   

WHEN:
                                 

February 3, 2012
                                   
                                   

- Press Conference at 8 AM CT
                                   

- SWIFT Presentation Dr Saver at 12 PM CT
                                   

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.comto learn more about our business.

Contacts

Covidien

Rachel Bloom Baglin, 508-452-6651

VP, Communications, Vascular Therapies

cell: 774-284-1193

rachel.bloombaglin@covidien.com



David T. Young, 508-452-1644

Manager, External Communications, Vascular Therapies

cell: 774-284-2746

david.young@covidien.com